Companies → Terns Pharmaceuticals, Inc.

Save to list

Remove

Terns Pharmaceuticals, Inc.

United States, Foster City

Report a bug?

Claim ownership and edit

Description

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Industries

Wood Product Manufacturing

SIC

Lumber and Wood Products, Except Furniture

Address:

1065 East Hillsdale Boulevard

Website:

www.ternspharma.com

Recent news:

Superstring Capital Invests $6.84M in Axsome Therapeutics in Q4 2025

Analysis of Superstring Capital Management's new $6.84 million investment in Axsome Therapeutics in late 2025, highlighting the biopharma firm's commercial portfolio and CNS focus.

Source: IndexBox Mar 18, 2026

Superstring Capital Management Acquires $7.43M Stake in Sionna Therapeutics

Analysis of Superstring Capital Management's Q4 2025 investment in Sionna Therapeutics, a clinical-stage biotech company developing cystic fibrosis treatments, based on recent SEC filings and financial data.

Source: IndexBox Mar 18, 2026

Superstring Capital Acquires $5.69M Stake in Definium Therapeutics

Analysis of Superstring Capital Management's new $5.69 million investment in Definium Therapeutics, a clinical-stage biopharma company, as reported in a Q4 2025 SEC filing.

Source: IndexBox Mar 18, 2026

Superstring Capital Trims Terns Pharmaceuticals Stake in Q4 2025

Analysis of Superstring Capital Management's Q4 2025 reduction of its Terns Pharmaceuticals position, detailing the transaction size, portfolio impact, and company context.

Source: IndexBox Mar 18, 2026

Vestal Point Capital Establishes $181.8M Stake in Terns Pharmaceuticals

Vestal Point Capital disclosed a major $181.8 million investment in Terns Pharmaceuticals, a biotech company developing treatments for NASH and obesity, now the firm's third-largest holding.

Source: IndexBox Mar 17, 2026

XNAS - Delayed Quote - USD

TERN

48.44 -0.62 (-1.26%)

At close March 23 06:40 UTC

Candle

Line

Financial Statistics

Valuation Measures

Current

Quarterly

As of 06/22/2025

Market Cap: 339.74 M

Enterprise Value: 6.72 M

Trailing P/E: N/A

Forward P/E: -2.81

PEG Ratio (5yr expected): N/A

Price/Sales (ttm): N/A

Price/Book (mrq): 1.04

Enterprise Value/Revenue: N/A

Enterprise Value/EBITDA: -0.07

Financial Highlights

Profitability and Income Statement

Profit Margin: N/A%

Return on Assets (ttm): -22.15%

Return on Equity (ttm): -32.12%

Revenue (ttm): N/A

Net Income Avi to Common (ttm): -90.39 M

Diluted EPS (ttm): -1.08

Balance Sheet and Cash Flow

Total Cash (mrq): 334.26 M

Total Debt/Equity (mrq): 0.38%

Levered Free Cash Flow (ttm): -44.95 M

Disclaimer:

IndexBox is not affiliated with, associated with, or endorsed by this company in any way. The information provided on this page, including company details, is solely for informational purposes. IndexBox makes no representations or warranties about the accuracy or completeness of the information provided.

All data and information is provided “as is” for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. Please consult your broker or financial representative to verify pricing before executing any trade. IndexBox is not an investment adviser, financial adviser or a securities broker. None of the data and information constitutes investment advice nor an offering, recommendation or solicitation by IndexBox to buy, sell or hold any security or financial product, and IndexBox makes no representation (and has no opinion) regarding the advisability or suitability of any investment.